InsiderTrades.com logo
James B. Tananbaum net worth and biography
  • LinkedIn

James Tananbaum Biography and Net Worth

Director of Latigo Biotherapeutics

Jim Tananbaum, M.D., is the founder and chief executive officer of Foresite Capital and Foresite Labs, a U.S.-focused healthcare investment firm with approximately $3.5 billion in assets under management. Tananbaum has been a thought partner for impactful and fast-growing companies, including Alumis, 10x Genomics, Element BioScience and Jazz Pharmaceuticals.

Tananbaum’s career in healthcare investment spans more than three decades. He has founded and led multiple successful companies, including GelTex, Inc., which brought two drugs to market and was acquired, and Theravance Inc. Tananbaum holds an M.D. from Harvard University, an M.B.A. from Harvard while playing rugby, and a B.S. and B.S.E.E. in applied math and electrical engineering/computer science from Yale University.

What is James B. Tananbaum's net worth?

The estimated net worth of James B. Tananbaum is at least $44.92 million as of August 10th, 2026. Tananbaum owns 2,008,024 shares of Latigo Biotherapeutics stock worth more than $44,919,497 as of August 21st. This net worth estimate does not reflect any other assets that Tananbaum may own. Learn More about James B. Tananbaum's net worth.

How do I contact James B. Tananbaum?

The corporate mailing address for Tananbaum and other Latigo Biotherapeutics executives is , ,. Learn More on James B. Tananbaum's contact information.

Has James B. Tananbaum been buying or selling shares of Latigo Biotherapeutics?

During the past quarter, James B. Tananbaum has bought $2,520,000.00 in Latigo Biotherapeutics stock. Most recently, on Monday, August 10th, James B. Tananbaum bought 140,000 shares of Latigo Biotherapeutics stock. The stock was acquired at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the transaction, the director now directly owns 2,008,024 shares of the company's stock, valued at $36,144,432. Learn More on James B. Tananbaum's trading history.

Are insiders buying or selling shares of Latigo Biotherapeutics?

In the last year, Latigo Biotherapeutics insiders bought shares 2 times. They purchased a total of 280,000 shares worth more than $5,040,000.00. The most recent insider tranaction occured on August, 10th when Major Shareholder Foresite Capital Management V, bought 140,000 shares worth more than $2,520,000.00. Learn More about insider trades at Latigo Biotherapeutics.

Information on this page was last updated on 8/10/2026.

James B. Tananbaum Insider Trading History at Latigo Biotherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/10/2026Buy140,000$18.00$2,520,000.002,008,024View SEC Filing Icon  
See Full Table

James B. Tananbaum Buying and Selling Activity at Latigo Biotherapeutics

This chart shows James B Tananbaum's buying and selling at Latigo Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Latigo Biotherapeutics Company Overview

Latigo Biotherapeutics logo
Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc. is based in THOUSAND OAKS, Calif.
Read More

Today's Range

Now: $22.37
Low: $20.64
High: $22.90

50 Day Range

MA: N/A

2 Week Range

Now: $22.37
Low: $17.22
High: $22.90

Volume

195,966 shs

Average Volume

250,267 shs

Market Capitalization

$1.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A